.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
McKesson
Merck
Harvard Business School
AstraZeneca
Moodys
Deloitte
Express Scripts
Julphar
Healthtrust

Generated: January 22, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR
AZILSARTAN KAMEDOXOMIL

« Back to Dashboard

Clinical Trial Listing

Trial ID Title Status Sponsor Phase Summary
NCT00362115 Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate HypertensionCompletedTakedaPhase 2 The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
NCT00376181 Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes MellitusTerminatedTakedaPhase 3 The purpose of this study is to evaluate the efficacy and safety of pioglitazone-azilsartan, once daily (QD), in subjects with type 2 diabetes mellitus with poor glycemic control.
NCT00591253 Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential HypertensionCompletedTakedaPhase 3 The purpose of this study is to evaluate the effectiveness and safety of azilsartan medoxomil compared to placebo, once daily (QD), in African-American participants with essential hypertension.
NCT00591266 Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential HypertensionCompletedTakedaPhase 3 The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine alone.
NCT00591578 Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential HypertensionCompletedTakedaPhase 3 The purpose of this study is to compare the efficacy and safety of TAK-491 (azilsartan medoxomil), once daily (QD), to valsartan in participants with essential hypertension.
NCT00591773 Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential HypertensionCompletedTakedaPhase 3 The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with chlorthalidone alone.
NCT00695955 One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential HypertensionCompletedTakedaPhase 3 This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
NCT00696241 Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential HypertensionCompletedTakedaPhase 3 The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil, once daily (QD), compared to placebo and olmesartan in participants with essential hypertension.
NCT00696384 A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential HypertensionCompletedTakedaPhase 3 The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.
NCT00696436 An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.CompletedTakedaPhase 3 The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Conditions

Condition Name

Condition Name for AZILSARTAN KAMEDOXOMIL
Intervention Trials
Hypertension 25
Essential Hypertension 9
Type 2 Diabetes Mellitus 2
Type 2 Diabetes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for AZILSARTAN KAMEDOXOMIL
Intervention Trials
Hypertension 34
Diabetes Mellitus 7
Diabetes Mellitus, Type 2 5
Angina Pectoris 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trial Locations

Trials by Country

Trials by Country for AZILSARTAN KAMEDOXOMIL
Location Trials
United States 405
Japan 42
Mexico 28
China 18
Germany 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for AZILSARTAN KAMEDOXOMIL
Location Trials
Ohio 18
Florida 17
California 17
Texas 17
South Carolina 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress

Clinical Trial Phase

Clinical Trial Phase for AZILSARTAN KAMEDOXOMIL
Clinical Trial Phase Trials
Phase 4 5
Phase 3 25
Phase 2/Phase 3 2
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for AZILSARTAN KAMEDOXOMIL
Clinical Trial Phase Trials
Completed 29
Recruiting 7
Terminated 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors

Sponsor Name

Sponsor Name for AZILSARTAN KAMEDOXOMIL
Sponsor Trials
Takeda 37
Lee's Pharmaceutical Limited 2
Arbor Pharmaceuticals, Inc. 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for AZILSARTAN KAMEDOXOMIL
Sponsor Trials
Industry 42
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Express Scripts
US Department of Justice
Deloitte
Harvard Business School
Colorcon
Argus Health
Moodys
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot